A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

Launched by NOVO NORDISK A/S · Aug 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called NNC0487-0111 to see how safe it is and how it works in the body when injected under the skin. The medicine is being tested in Chinese men who are overweight or have obesity, with a body mass index (BMI) between 24 and 34.9. The study will last about 53 days, and participants will either receive the new medicine or a placebo, which is a harmless injection without any active medicine. Whether a participant gets the medicine or placebo is decided randomly.

To take part, men need to be between 18 and 55 years old, be Chinese, and have a BMI in the specified range with a body weight of at least 65 kilograms (around 143 pounds). Participants also need to be generally healthy based on medical exams and lab tests. During the study, participants will be monitored closely for safety. This trial is not yet recruiting, and it is important to know that the new medicine is still being tested and is not available for general use outside the study.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
• • 2. Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent.
• • 3. Body mass index between 24.0 and 34.9 kg/m2 (both inclusive) at screening. Overweight and obesity should be due to excess adipose tissue, as judged by the investigator, with a body weight (more than or equal to) ≥ 65.0 kg at screening.
• • 4. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
• Exclusion Criteria:
• • 1. Any condition, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• • 2. HbA1c ≥ 6.5 percent (%) \[48 milimol per mole (mmol/mol)\] at screening.
• 3. Any laboratory safety parameters at screening outside the below laboratory ranges:
• • Vitamin D (25-hydroxycholecalciferol) less than (\<) 12 nanogram per mililiter (ng/mL) \[30 nanometer (nM)\] at screening
• • Parathyroid hormone (PTH) outside normal range at screening
• • Total calcium outside normal range at screening
• • Amylase ≥ 2 times upper limit of normal at screening
• • Lipase ≥ 2 times upper limit of normal at screening
• • Calcitonin ≥ 50 picogram per mililiter (pg/mL) at screening